Type XVI Collagen is Expressed in Factor XIIIa+ Monocyte-Derived Dermal Dendrocytes and Constitutes a Potential Substrate for Factor XIIIa  by Akagi, Atsushi et al.
Type XVI Collagen is Expressed in Factor XIIIa+
Monocyte-Derived Dermal Dendrocytes and Constitutes a
Potential Substrate for Factor XIIIa
Atsushi Akagi, Shingo Tajima, Akira Ishibashi, Yuko Matsubara,* Makoto Takehana,* Shizuko Kobayashi,* and
Noriko Yamaguchi²
Department of Dermatology, National Defense Medical College, Saitama, Japan; *Department of Physiology and Anatomy, Kyoritsu College of
Pharmacy, Tokyo, Japan; ²Department of Molecular Pathogenesis, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan
We have previously reported that connective tissue
cells in the super®cial dermis preferentially express
a1(XVI) collagen rather than those in the lower
dermis. Double immuno¯uorescence labeling using
the antibodies for a1(XVI) collagen and factor XIIIa
(plasma transglutaminase), which is a marker of
dermal dendrocytes, demonstrated that both anti-
bodies reacted with the same cells in the super®cial
dermis of normal skin as well as the lesional skins
of dermal dendrocyte-related disorders, dermato-
®broma, and psoriasis. Dermal dendrocytes are con-
sidered to be established by a culture of peripheral
blood monocytes in the presence of granulocyte
macrophage-colony stimulating factor and inter-
leukin-4. Reverse transcription±polymerase chain
reaction, metabolic labeling, and immuno¯uores-
cence studies demonstrated that treatment of CD14+
peripheral blood monocytes with granulocyte
macrophage-colony stimulating factor/interleukin-4
over a period of 8 d resulted in the induction of
a1(XVI) collagen as well as factor XIIIa. The physio-
logic signi®cance of colocalization of a1(XVI) col-
lagen and factor XIIIa in the tissue and their
coordinate induction in CD14+ monocyte-derived
dendritic cells in vitro was studied. Considerable
incorporation of [3H]putrescine by factor XIIIa into
recombinant noncollagenous domain (NC) 11 but
not into collagenous domain (COL) 1´NC1 domain
of the a1(XVI) polypeptide was found. Incubation of
recombinant NC11 of a1(XVI) polypeptide with fac-
tor XIIIa in vitro produced a covalent cross-linking
complex on sodium dodecylsulfate±polyacrylamide
gel electrophoresis. The results indicate that a1(XVI)
collagen is constitutively expressed by most dermal
dendrocytes in the skin and dendritic cells differenti-
ated from peripheral blood monocytes in vitro. Type
XVI collagen is expressed in factor XIIIa+ dermal
dendrocytes and may form an intermolecular cross-
linking through NC11 domain by the reaction cata-
lyzed by factor XIIIa contributing to the structural
integrity of factor XIIIa+ dendritic cell-rich tissues.
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O
n the basis of structure and function, collagens are
generally divided into ®bril-forming collagens and
non®bril-forming collagens. Unlike ®bril-forming
collagens, non®bril-forming collagens are very
heterogeneous in size and have imperfections in
the GLy±X±Y repeating sequence as a common feature. In the latter
class, type IX, XII, and XIV collagens form a subgroup named the
®bril-associated collagens with interrupted triple helices (FACIT)
(Vuorio and Crombrugghe, 1990; Fukai et al, 1994). Type XVI
collagen polypeptide designated as a1(XVI) consists of 10
collagenous domains, which were interspersed with 11 noncolla-
genous domains exhibiting several structural features characteristi-
cally seen in members of FACIT (Pan et al, 1992; Yamaguchi et al,
1992). It has been shown that the FACIT members are localized on
the surface of major collagen ®brils and may serve as molecular
bridges that are responsible for maintaining the structural integrity of
the extracellular matrices. Although the structural similarities
between FACIT and type XVI collagen may suggest similar
function, no information on its physiologic function is available.
Type XVI collagen in the adult mouse has been demonstrated to
distribute widely in the heart, kidney, intestine, ovary, testis, eye,
arterial wall, and smooth muscle (Lai and Chu, 1996), supporting the
fact that collagen may contribute to the structural integrity of various
tissues. In the skin, it has been demonstrated that speci®c type XVI
collagen gene transcripts and its biosynthesis are detected in cultured
dermal ®broblasts and keratinocytes, and its expression is closely
related to cell growth arrest (Grassel et al, 1996, 1998; Tajima et al,
2000). By an immunohistochemical study, we and colleagues have
previously demonstrated that the antibody against a1(XVI) chain
reacted preferentially with the ®xed connective tissue cells and
matrix in the papillary dermis rather than those in the reticular
dermis (Akagi et al, 1999; Grassel et al, 1999), suggesting that type
XVI collagen-positive cells in the papillary dermis may represent a
speci®c phenotype of the connective tissue cells.
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Dendritic cells are de®ned as a group of cells that are bone
marrow-derived, express major histocompatibility complex class II
antigens, show little or no endocytotic or phagocytic activity, and
display potent accessory function in antigen presentation.
Cutaneous cells with dendritic morphology include cells that
reside primarily in the epidermal layer, such as Langerhans cells and
poorly de®ned cells of similar contour in the underlying dermis
[dermal dendrocytes (DD)] (Headington, 1986; Hoyo et al, 1993).
DD express several monocyte/macrophage markers. These features
along with the expression of major histocompatibility complex class
II antigens have promoted the speculation that DD represent a
subset of dendritic, antigen-presenting macrophages (Nickoloff,
1991). It has been demonstrated that the treatment of CD14+
peripheral blood monocytes with granulocyte/macrophage-colony
stimulating factor (GM-CSF) and interleukin (IL)-4 induces
differentiation into dendritic cells (DD), which express coagulation
factor XIIIa (FXIIIa; plasma transglutaminase) (Young et al, 1990;
Sallusto and Lanzavecchia, 1994). On the other hand, it has been
reported that DD arise from embryonic mesenchymal cells and
represent a population of resident cells of the dermis identi®ed by
virtue of the immunohistochemical expression of FXIIIa (Gibran et
al, 1996). FXIIIa-positive cells are present preferentially in the
papillary dermis around the super®cial blood vessels in normal skin
(Cerio et al, 1989a; Nestle et al, 1993). Although the question
whether DD represent a subset of dendritic monocytes or unique
skin resident cells with distinctive characteristics remains to be
answered, these cells appear to be of critical importance in
cutaneous pathophysiology. For example, increased number or size
of DD has been identi®ed in various skin disorders: psoriasis and
atopy (Cerio et al, 1989a), Kaposi's sarcoma associated with the
acquired immune de®ciency syndrome (Nickoloff and Grif®ths,
1989), dermato®broma (Cerio et al, 1989b), acute graft versus host
disease (Yoo et al, 1998), morphea, and scars (Gilmour et al, 2000).
Coagulation FXIII is a protransglutaminase involved in the ®nal
stage of the coagulation pathway. FXIII is a tetrameric protein
consisting of two pairs of subunits (two a and two b) with the
enzyme activity present in subunit a (FXIIIa) (Muszbek et al, 1996;
Aeschlimann and Thomazy, 2000). It has been shown that FXIIIa
stabilizes clot formation by cross-linking ®brin, ®bronectin to
collagen types I, II, III, and V, or von Willebrand factor to collagen
(Mosher et al, 1980; Mosher, 1984; Bockenstedt et al, 1986). There
have been no previous reports describing collagen±collagen cross-
linking of collagenous protein itself by FXIIIa.
The restricted localization of the FXIIIa-positive and a1(XVI)
collagen-positive cells in the super®cial dermis suggests that they
share a common phenotype of the connective tissue cells in the
papillary dermis. This led us to study immunohistochemically
normal skin as well as DD-related skin diseases using both anti-
FXIIIa and anti-type XVI collagen antibodies. In addition, based
upon the demonstration that DD are induced to differentiate from
cultured CD14+ peripheral blood monocytes, we tried to detect
a1(XVI) mRNA or its polypeptide synthesis in the cultured
peripheral blood monocytes treated with GM-CSF and IL-4.
Finally, we attempted to study whether type XVI collagen is a
potent substrate for FXIIIa -mediated cross-linking.
MATERIALS AND METHODS
Tissue samples Skin samples were obtained from normal volunteers
(n = 4) (ages; 28±35, male/female; 4:0) or the patients with
dermato®broma (n = 4) (ages; 21±40, male/female; 3:1), or psoriasis
vulgaris (n = 4) (ages; 41±54, male/female; 4:0). Diagnosis of
dermato®broma and psoriasis was made by typical histologic features.
Double immuno¯uorescence labeling of the skin or cultured
peripheral blood monocytes The skin specimens were embedded in
optimal cutting temperature (OCT) compound (Sakura Finetechnical,
Japan) and snap-frozen. The specimens were cut into 5 mm sections and
®xed with acetone. CD14+ peripheral blood monocytes (See below)
were cultured on the slide glass (Becton Dickinson Labware, Franklin
Lakes, NJ) and ®xed with acetone. The samples were incubated with
both rabbit af®nity-puri®ed anti-a1(XVI) collagen antibody raised against
synthetic peptide TQPTRRVFPRGLPEEFAL in the N-terminal
noncollagenous domain (NC11) of a1(XVI) polypeptide (Akagi et al,
1999) and sheep anti-human FXIIIa antibody (Enzyme Research
Laboratories, South Bend, IN) for 24 h at 1:500 dilution for anti-
a1(XVI) collagen antibody or 1:100 dilution for anti-FXIIIa antibody.
The sections or cultured cells were incubated with rhodamine-
conjugated swine anti-rabbit IgG (Dako, Glostrup, Denmark) at 1:40
dilution and ¯uorescein isothiocyanate-conjugated donkey anti-sheep
IgG (Chemicom, Temecula, CA) at 1:50 dilution for 2 h, then washed
with phosphate-buffered saline exhaustively. Evaluation of ¯uorescence
was performed with a confocal laser scan microscope (LSM410, Carl
Zeiss, Jena, Germany). The number of a1(XVI)+ or FXIIIa+ cells in the
skin specimens or cultured peripheral blood monocytes was calculated
from the observation of 50 cells in a random, nonoverlapping ®eld under
a microscope. Values were obtained from four different skin samples or
four different culture dishes. Statistical study was performed using one-
sided Student's t test and statistical signi®cance at p < 0.01 was
considered to be signi®cant.
Culture of peripheral blood monocytes Peripheral blood was
obtained from normal donors. Peripheral blood mononuclear cells were
isolated by Ficoll-Paque (Pharmacia, Uppsala, Sweden) gradient
centrifugation. Peripheral blood mononuclear cells (1 3 108) were
incubated with 200 ml of microbeads conjugated with monoclonal
antihuman CD14 antibody in 800 ml of MACS buffer [phosphate-
buffered saline/2 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0/
0.5% bovine serum albumin (BSA)] at 4°C for 30 min. The cells
immobilized with CD14 microbeads were separated by a magnetic cell
separator (MidiMACS, Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany) according to the manufacturer's protocol. More than 90%
purity of CD14+ cells was routinely obtained. The CD14+ cells were
plated in six-well or 10 cm diameter tissue culture plates (Becton
Dickinson Labware) at a density of 2 3 106 cells per plate in 3 ml or
10 ml of RPMI medium containing 10% fetal bovine serum and
incubated at 37°C for 4 h in a humidi®ed atmosphere and CO2. After
aspiration of nonadherent cells, adherent cells were treated for 0, 4, and
8 d with recombinant GM-CSF (10 ng per ml) (Genzyme, Cambridge,
MA) and recombinant IL-4 (10 ng per ml) (Genzyme) in RPMI
medium containing 10% fetal bovine serum (Young et al, 1990; Sallusto
and Lanzavecchia, 1994).
Reverse transcription±polymerase chain reaction (RT±PCR)
assay Total cellular RNA was isolated as described previously
(Chomczynski and Sacchi, 1987). Ten micrograms of total RNA was
treated with 1 unit of DNase I (Ambion, Austin, TX) for 15 min and
inactivated with EDTA. RT±PCR was performed with a 5¢ primer [5¢
CTGTGGCTGTAGCTGACCTC3¢ (nucleotide number 123±142)] and
a 3¢ primer [5¢ AGATGCAGGACACAAAGTCG3¢ (nucleotide number
606±625)] based on the sequence of NC11 domain of human a1(XVI)
cDNA (Pan et al, 1992), or with a 5¢ primer [5¢GGGAAG-
CTTTCAGAAACTTCCAGGACCGCCTTTGG3¢ (nucleotide number
88±109)] and a 3¢ primer [5¢GGAATTCCTGGATGGACAGCCGCA-
CAGACCTGTC3¢ (nucleotide number 502±526)] corresponding to the
5¢ end sequence of human FXIIIa cDNA (Grundmann et al, 1986). The
®rst strand cDNA was synthesized using total RNA (1 mg per assay), a 3¢
primer and reverse transcriptase at 42°C for 1 h. The reaction was run
for 35 cycles with denaturation at 94°C for 1 min, annealing at 62°C for
2 min, and extension at 72°C for 5 min in a DNA thermal cycler
(Perkin Elmer Cetus, Norwalk, CT) (Kawasaki, 1990). The quality of
the cDNA synthesis was monitored by amplifying the human
glyceraldehyde-3-phosphate-dehydrogenase gene. The primer sequences
of glyceraldehyde-3-phosphate-dehydrogenase were: 5¢ primer (5¢GAA-
GGTGAAGGTCGGAGTC3¢) and 3¢ primer (5¢GAAGATGGTGAT-
GGGATTTC3¢) (Maxim Biotech, San Francisco, CA). Ampli®cation for
glyceraldehyde-3-phosphate-dehydrogenase was carried out with 28
cycles of 1 min denaturation at 94°C, 1 min annealing at 62°C, and
1 min extension at 72°C. The reverse transcription±PCR products were
analyzed by an electrophoresis on 1% agarose. DNA fragments ampli®ed
by PCR were extracted from agarose gel and ligated into the plasmid
vector (pCRII) (Invitrogen, Carlsbad, CA). The constructs were
transformed into an Escherichia coli strain JM109 (Invitrogen). The
plasmid DNA was puri®ed with Wizard plus minipreps (Promega,
Madison, MI) and sequenced by the dideoxy chain termination method
using a Sequenase kit (Sanger et al, 1977). The nucleotide sequences
were found to be identical to those previously reported (Grundmann
et al, 1986; Pan et al, 1992).
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Biosynthesis of a1(XVI) collagen CD14+ cultured monocytes that
had been treated with or without GM-CSF/IL-4 for 8 d were labeled
with [35S]methionine (40 TBq per mmol; Amersham Pharmacia Biotech,
Buckinghamshire, U.K.) for 24 h in RPMI medium de®cient in fetal
bovine serum and L-methionine supplemented with 30 mg per ml
ascorbic acid. For comparison, ®broblasts obtained from fetus skin
established from a routine explant method were labeled with
[35S]methionine as well. Culture medium was harvested and mixed with
protease inhibitor cocktails (1 mM EDTA, 1 mM N-ethylmaleimide,
and 1 mM phenylmethylsulfonyl ¯uoride), then stored at ±80°C until
use. Cells were homogenized in 50 mM Tris±HCl, pH 7.4, 1 mM
EDTA, 1 mM N-ethylmaleimide, 1 mM phenylmethylsulfonyl ¯uoride,
and 0.3% nonidet P-40 at 4°C. The supernatant of cell pellet and culture
medium was individually applied to the anti-a1(XVI) NC11 antibody
column (Akagi et al, 1999). Bound proteins were eluted with 0.1 M
citrate buffer at pH 6.0, pH 5.0, pH 4.0, and pH 3.0. The elution of the
proteins was monitored by liquid scintillation spectrometer (Beckman LS
9800, Beckman Coulter, Fullerton, CA). Preliminary experiments
showed that most of the radioactivity (more than 92%) was eluted at
pH 3.0. The fraction of pH 3.0 was lyophilized and subjected to 5±20%
gradient sodium dodecylsulfate±polyacrylamide gel electrophoresis (SDS±
PAGE). The gels were ®xed in methanol/acetic acid, dried in vacuo, then
subjected to autoradiography for 48 h at ±80°C.
Western blot assay of FXIIIa in cultured monocytes CD14+
peripheral blood monocytes treated without or with GM-CSF/IL-4 for
8 d were washed with phosphate-buffered saline three times, then further
cultured in serum-free RPMI medium for 24 h. Conditioned medium
was mixed with protease inhibitor cocktails, then the proteins were
precipitated with 50% ammonium sulfate (313 mg per ml). Cells were
trypsinized and suspended in 10 mM Tris±HCl, pH 7.4, 1 mM EDTA,
then disrupted by sonication (Handy Sonic UR-20P, Tomy Seiko Co.,
Tokyo, Japan) with ®ve 30 s bursts at 4°C. Insoluble materials were
pelleted by centrifugation at 10,000 3 g for 20 min and the proteins in
the supernatant were precipitated with 10% trichloroacetic acid. The
pellets in the medium and cells were dissolved in 0.1 M Tris±HCl,
pH 8.5 containing 1% SDS, boiled at 90°C for 2 min, then resolved on
a 5±20% gradient SDS±PAGE in the reducing condition. Protein content
in the medium and cell lysate was determined with the protein assay kit
(Bio-Rad Laboratories, Hercules, CA) with bovine serum albumin as the
standard, and the concentration of the sample was adjusted to be
equivalent in each well of SDS±PAGE. The proteins isolated from
culture medium and cells of established human skin ®broblasts, as well as
FXIIIa generated by the reaction of FXIII and thrombin, and tissue
transglutaminase prepared from liver (Sigma, St Louis, MO) were also
subjected to 5±20% gradient SDS±PAGE under a reducing condition.
The samples were electrophoretically transferred from gels to
nitrocellulose membrane (Schleicher & Schuell, Keene, NH) (Towbin et
al, 1979). The membranes were incubated with anti-FXIIIa antibody at
1:1000 dilution for 1 h, and then reacted with anti-sheep IgG at 1:2000
dilution for 1 h. Antigen±antibody was visualized by a
chemiluminescence kit (Amersham Pharmacia Biotech).
Preparation of recombinant COL1´NC1 and NC11 of a1 (XVI)
molecule For the expression of the amino terminal ¯ag tagged
COL1´NC1 (amino acids 1472±1603) and NC11 (amino acids 22±333)
domains of a1(XVI) collagen, DNA fragments were ampli®ed by PCR
using the cDNA clones NYh-4 (Yamaguchi et al, 1992) and NYh-6
isolated from human heart cDNA library (Clontech, Palo Alto, CA)
(unpublished data) as templates and primers with a NheI and NotI
restriction site at the ends. The following primers were chosen for each
of the two recombinant peptides of a1(XVI) collagen: ¯ag tagged
COL1´NC1 fragment, 5¢ primer [5¢ AGCGCTAGCTGACTACAA-
GGACGACGATGACAAGGGACGACCAGGGCCTCCAGGGAAG3¢
(nucleotide number 193±240)] and 3¢ primer [5¢GTCGGCGGCC-
GCGAATTTCAGCCAAAAGGCCCCT3¢ (nucleotide number 1130±
1152)]; ¯ag tagged NC11 fragment, 5¢ primer [5¢AGCGCTAGCTGA-
CTACAAGGACGACGATGACAAGGCAAATACAGGTGCACAAT-
GCCCA3¢ (nucleotide number 4567±4590)] and 3¢ primer [5¢GTC-
GGCGGCCGCGGTGGCTAAGAGGGAGCAAGTGTGACATTGC3¢
(nucleotide number 4949±4970)]. We sequenced the entire PCR
products and found an identical sequence to the previously published
one. The PCR products were cloned into the modi®ed episomal
expression vector pCEP-Pu (Kofeldt et al, 1997). Human embryonic
kidney cells (293-EBNA) were purchased from Invitrogen and used for
transfection. Stably transfected cells were selected by 0.5 mg per ml of
puromycin, and serum-free conditioned medium was collected
(Yamaguchi et al, 1999). Conditioned medium was dialyzed against
50 mM Tris±HCl, pH 7.5, 0.15 M NaCl and passed over a column
immobilized with anti-FLAG antibody (Sigma). Bound proteins were
eluted with 0.1 M glycine±HCl, pH 3.5 and neutralized immediately
after elution. Puri®ed COL1´NC1-N¯ag and NC11-N¯ag were dialyzed
against phosphate-buffered saline. Purity of recombinant proteins was
evaluated by SDS±PAGE. Identi®cation of recombinant a1(XVI) NC11
polypeptide was performed by western blot analysis using anti-a1(XVI)
antibody raised against synthetic peptides of the NC11 domain (Akagi et
al, 1999) and partial N-terminal amino acid sequence using a protein
sequencer (Beckman LF3000).
Incorporation of [3H]putrescine by FXIIIa into collagenous and
noncollagenous proteins Pepsin-solubilized human skin collagens
type I and III (Fuji Pharmaceutical, Toyama, Japan) dissolved in 50 mM
Tris±HCl pH 7.4, 0.15 M NaCl were heat denatured at 60°C for 1 h to
produce a-chains. Plasma ®bronectin was purchased from Life
Technology (Grand Island, NY). FXIII prepared from human plasma
was purchased from Cortex Biochem (San Leandro, CA). N,N¢-
dimethylcasein, BSA and thrombin were obtained from Sigma.
Incorporation of [1,4-3H]putrescine (1.0 TBq per mmol; Amersham) by
FXIIIa into various collagenous and noncollagenous polypeptides was
determined according to the method of Bowness et al (1987). Activation
of FXIIIa was performed by incubating 1 mg of FXIII per ml with
0.1 mg thrombin per ml at 37°C for 15 min in 0.1 M Tris±HCl, pH 8.5,
5 mM CaCl2 in a total volume of 40 ml. One microliter of FXIIIa
solution was added to the reaction mixture consisting of [3H]putrescine
(7 mCi/1.8 mM), protein substrates (750 nM) in the buffer (0.1 M Tris±
HCl, pH 8.5 containing 5 mM CaCl2 and 1 mM dithiothreitol) and
incubated at 37°C for 0, 30, 60, and 120 min. An enzyme blank
containing all reagents with excess EDTA (50 mM) was run with each
set of tubes. FXIIIa was used as a control substrate to measure the
autocatalytic reaction of FXIII itself. After incubation, the proteins were
precipitated with 10% trichloroacetic acid at 4°C. The precipitates were
washed with 10% trichloroacetic acid four times, then with ethanol/
ether (1:1) once. The proteins in the precipitates were dissolved with 1%
SDS by boiling for 2 min, and the radioactivities were counted with
liquid scintillation spectrometer (Beckman LS 9800). Three individual
assays were performed in duplicate.
Cross-linking formation of recombinant NC11 domain of a1(XVI)
polypeptide by FXIIIa Activation of FXIIIa was performed as
described above. NC11 fragment (1 mg), plasma ®bronectin (1 mg) or
type III collagen (Fuji Pharmaceutical) 1 mg was incubated with FXIIIa
solution at 37°C for 60 min in 0.1 M Tris±HCl, pH 8.5, 5 mM CaCl2
in a total volume of 20 ml. Control experiments were set up by deletion
of thrombin, CaCl2, or a1(XVI) NC11. The reaction products were
denatured by heating at 100°C for 1 min and resolved on 10±20%
gradient SDS±PAGE under a reducing condition, then blotted on to the
membranes. The membrane was incubated with anti-a1(XVI) NC11
rabbit antibody at 1:1000 dilution, with anti-®bronectin rabbit antibody
(Dako) at 1:2000 dilution or with anti-type III collagen mouse antibody
(Fuji Pharmaceutical) at 1:1500 dilution for 1 h, then reacted with
peroxidase conjugated secondary antibody at 1:2000 dilution for 1 h.
Antigen±antibody complex was detected by chemiluminescence
(Amersham Pharmacia Biotech).
RESULTS
Localization of a1(XVI)+ and FXIIIa+ cells in the dermis In
normal skin, anti-FXIIIa antibody reacted with the cells with a
dendritic morphology in the upper dermis as has been previously
reported (Cerio et al, 1989a; Nickoloff and Grif®ths, 1989; Nestle et
al, 1993; Gilmour et al, 2000) (Fig 1a). Anti-a1(XVI) collagen
antibody recognized the majority of FXIIIa-positive cells (Fig 1b),
but the antibody also recognized a few FXIIIa-negative cells in the
super®cial dermis (arrow in Fig 1b). There was a negligible
population of a1(XVI)±/FXIIIa+ in the super®cial dermis. The
antibody did not react with epidermal Langerhans cells (not shown)
but reacted weakly with epidermis, which is consistent with a
previous study (Grassel et al, 1999). As dermato®broma is
considered to have originated from FXIIIa+ DD and is referred
to as dermal dendrocytoma (Cerio et al, 1989b), skin specimens
from dermato®broma were subjected to immunohistochemical
analysis with anti-a1(XVI) antibody. In the lesional skin of
dermato®broma, majority of tumor cells were positive with both
anti-a1(XVI) collagen and anti-FXIIIa antibodies (Fig 1c, d). A
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few a1(XVI)+/FXIIIa± cells were found (arrows in Fig 1d). There
were no a1(XVI)±/FXIIIa+ cells. In psoriatic skin, the increase in
the number of FXIIIa+ DD has been demonstrated (Cerio et al,
1989a). In lesional skin of psoriasis, similar results to those of
normal skin were obtained except for the relatively abundant
number of FXIIIa+ or a1(XVI)+ cells (Fig 1e, f). Determination of
the number of cells positive for either anti-a1(XVI) collagen or
anti-FXIIIa antibody in normal skin showed that the populations of
a1(XVI)+/FXIIIa+ were predominant and comprise 71 6 5%,
whereas a1(XVI)+/FXIIIa± and a1(XVI)±/FXIIIa+ comprise
23 6 3% and less than 2 6 1%, respectively. The cell
populations in dermato®broma and psoriatic skin were similar to
those of normal skin (Fig 2).
Induction of a1(XVI) and FXIIIa in CD14+ monocyte-
derived dendritic cells To con®rm that the majority of DD in
the dermis consist of a1(XVI)+FXIIIa±cells, an in vitro culture
system was employed, which induces the differentiation of
peripheral blood monocytes into dendritic cells. RT±PCR using
a1(XVI) NC11-speci®c primer pairs showed a very faint DNA
fragment with 493 bp in the adherent cells prior to treatment
(Fig 3a, lane 0). Treatment of adherent CD14+ peripheral blood
monocytes with GM-CSF/IL-4 for 8 d relatively increased 493 bp
DNA fragment (Fig 3a, lane 8). The induction appeared to be
dependent on the period of the treatment (Fig 3a). The intensity of
DNA fragment with 441 bp produced by RT±PCR using FXIIIa-
speci®c primers was also relatively increased time-dependently after
8 d treatment (Fig 3b). A low degree of FXIIIa mRNA was
detectable by RT±PCR in the cells before the treatment with
GM-CSF/IL-4 (Fig 3b, lane 0), which is consistent with previous
reports that some extent of FXIIIa is expressed in circulating
peripheral blood monocytes (Henriksson et al, 1985; Weisberg et al,
1987). FXIIIa mRNA was not detected in the cultured skin
®broblasts (Fig 3b, lane F).
Immunoaf®nity assay using anti-a1(XVI) NC11 antibody col-
umn showed four distinct polypeptides with the molecular weights
of 220, 180, 130, and 62 kDa in both medium and cell layer
fractions in the treated monocytes, whereas no immunoreactive
polypeptide was detected in the untreated (control) monocytes. In
dermal ®broblasts, four immunoreactive polypeptides with the
same molecular sizes were detected (Fig 4a). We considered
220 kDa polypeptide as an intact a1(XVI) collagen chain, and 180
(Grassel et al, 1996), 130, and 62 kDa polypeptides as proteolyti-
cally processed a1(XVI) chains.
Figure 1. Double immuno¯uorescence of normal skin and
lesional skins of dermato®broma and psoriasis with anti-a1(XVI)
collagen and anti-FXIIIa antibodies. Cryostat sections of the skin
specimens taken from normal skin (a, b), dermato®broma (c, d), and
psoriasis (e, f) were incubated with the antibodies [rabbit anti-a1(XVI)
NC11 collagen antibody at 1:500 dilution and sheep anti-FXIIIa
antibody at 1:100 dilution] for 24 h at 4°C. The sections were incubated
with ¯uorescein isothiocyanate-conjugated anti-sheep IgG and
rhodamine-conjugated anti-rabbit IgG for 2 h. Evaluation of
¯uorescence was performed with a confocal laser scan microscope. (a, c,
e) Anti-FXIIIa antibody. (b, d, f) Anti-a1(XVI) NC11 collagen antibody.
Solid line in a, b, e, f indicates dermoepidermal junction.
Dermoepidermal junction was identi®ed by anti-type IV collagen
antibody. Original magni®cation, 3 200. a1(XVI)+/FXIIIa± population
was indicated by arrows (b, d, f). Scale bar: 50 mm.
Figure 2. Determination of a1(XVI)-positive or FXIIIa-positive
cells in normal skin, dermato®broma, and psoriatic skin. Skin
specimens taken from normal individual (upper panel), dermato®broma
(middle panel), and psoriatic patient (lower panel) were immunoreacted
with both anti-a1(XVI) NC11 collagen and anti-FXIIIa antibodies. The
number of positive cells was counted from the observation of 50 cells in
random, nonoverlapping ®elds of four different samples. Values indicate
mean 6 SEM.
270 AKAGI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
To know whether FXIIIa is induced in the dendritic cells
differentiated from monocytes, the proteins prepared from the
medium and cell lysate of cultured monocytes were analyzed by
western blot analysis using anti-FXIIIa antibody. Western blot
demonstrated that anti-FXIIIa antibody speci®cally reacted with
authentic FXIIIa with a molecular weight of 82 kDa, but did not
cross-react with tissue transglutaminase. FXIIIa levels in both
culture medium and cell lysate were extremely enhanced in the
treated monocytes compared with the untreated monocytes. No
detectable FXIIIa level was found in the medium and cells of
cultured ®broblasts (Fig 4b).
Treatment of adherent CD14+ peripheral blood monocytes with
GM-CSF/IL-4 resulted in a change of cell shape.
Immuno¯uorescence labeling of cultured CD14+ monocytes
demonstrated that the antibodies for a1(XVI) collagen and
FXIIIa reacted with identical cells. The number of
a1(XVI)+FXIIIa±cells was very few before the treatment (1.8±
2.5% of total cells), but markedly increased (97±99% of total cells)
after treatment for 8 d (Fig 5).
Recombinant NC11 domain of a1(XVI) is a potential
substrate for FXIIIa The localization of FXIIIa+ and
a1(XVI)+ cells in the super®cial connective tissue cells in vivo and
Figure 5. Immunostaining of cultured
peripheral blood monocytes with anti-
a1(XVI) collagen and anti-FXIIIa antibodies.
CD14+ peripheral blood monocytes were plated
and treated with GM-CSF (10 ng per ml) and IL-
4 (10 ng per ml) for 0 and 8 d. Cells were ®xed
with acetone, then incubated with anti-FXIIIa (a,
c) and anti-a1(XVI) collagen (b, d) antibodies. (a,
b) Immunostaining prior to treatment with GM-
CSF/IL-4; (c, d) Immunostaining after treatment
with GM-CSF/IL-4. Original magni®cation
3 120. Scale bar: 50 mm.
Figure 4. Biosynthesis of a1(XVI) collagen and FXIIIa in the
dendritic cells differentiated from peripheral blood monocytes.
CD14+ peripheral blood monocytes were plated and treated with GM-
CSF (10 ng per ml) and IL-4 (10 ng per ml) for 0 and 8 d. (a) Cells
were labeled with [35S]methionine for the ®nal 24 h (Treated Mo). For
control experiments (treatment for 0 d), adherent monocytes were
labeled for 24 h in the absence of GM-CSF and IL-4 (Control Mo). For
comparison, cultured normal skin ®broblasts were grown to con¯uent
density, then labeled with [35S]methionine for 24 h (FB). Culture
medium and cells were harvested, then the proteins were adsorbed with
anti-a1(XVI) NC11 antibody column and resolved on SDS±PAGE
under a reducing condition. The gels were processed to autoradiography.
(b) Cells before (Control Mo) or after the treatment (Treated Mo) with
GM-CSF/IL-4 were incubated with serum-free medium for 24 h.
Proteins in the conditioned medium and cell lysate harvested from
treated and untreated monocytes were resolved on SDS±PAGE under a
reducing condition, blotted on to the ®lters, then incubated with anti-
FXIIIa antibody. For comparison, conditioned medium and cell lysate of
cultured skin ®broblasts were also subjected for analysis (FB). Authentic
FXIIIa and tissue transglutaminase were subjected to western blot analysis
as positive and negative controls, respectively. M, medium fraction; C,
cell fraction.
Figure 3. Expression of a1(XVI) and FXIIIa in cultured
peripheral blood monocytes treated with GM-CSF/IL-4. CD14+
peripheral blood monocytes were isolated, then plated in tissue culture
plate. Adherent cells were received the treatment of GM-CSF (10 ng per
ml) and IL-4 (10 ng per ml) for 0, 4, and 8 d. Control cells (treatment
for 0 d) indicate adherent cells after 4 h of inoculation. Total cytoplasmic
RNA was isolated from the cells, and 10 mg of total RNA was treated
with DNase I for 15 min. Reverse transcription±PCR was performed
using (a) a1(XVI) collagen, (b) FXIIIa or (c) glyceraldehyde-3-phosphate-
dehydrogenase speci®c oligomers as primers. PCR products were
resolved by electrophoresis on 1% agarose gel. Lane F indicates positive
control assay using the RNA extracted from cultured normal skin
®broblasts. Lane M indicates molecular markers.
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coordinate expression of a1(XVI) and FXIIIa in the monocyte-
derived dendritic cells led us to investigate whether the a1(XVI)
chain can be a potential substrate for FXIIIa. We determined the
incorporation of [3H]putrescine by FXIIIa into two different
domains (COL1´NC1 and NC11) of the a1(XVI) polypeptide with
BSA and type I and type III collagens as negative controls (Bowness
et al, 1987), and two well-characterized transglutaminase substrates
N,N¢-dimethylcasein and plasma ®bronectin as positive controls
(Fesus et al, 1986; Bowness et al, 1987; Aeschlimann and Paulsson,
1991). Incubation of COL1´NC1 domain of a1(XVI) with FXIIIa
gave only background levels of incorporation, comparable with the
reaction with BSA and type I and type III collagens. In contrast, the
NC11 domain of a1(XVI) showed a signi®cant incorporation of
[3H]putrescine to the extent comparable with ®bronectin, but to a
lesser extent than dimethylcasein. A low degree of autocatalytic
reaction of FXIII was found (Fig 6).
To investigate further whether FXIIIa actually mediates covalent
cross-linking of the a1(XVI)NC11 domain, this domain was
incubated with FXIIIa, and reaction products were analyzed by
SDS±PAGE under a reducing condition. We used ®bronectin as a
positive control and type III collagen as a negative control. Western
blot analysis using anti-a1(XVI) NC11 antibody showed that
a1(XVI) NC11 formed high molecular complexes in addition to
the intact a1(XVI) NC11 domain (35 kDa). The apparent
molecular weight of the complexes ascertained by SDS±PAGE
were 72 kDa and > 1 3 106 kDa (at the top of the gel) (Fig 7a,
lane 1). These complexes were not found when the incubation
mixture lacked thrombin (Fig 7a, lane 2), Ca ion (Fig 7a, lane 3),
and substrate (a1(XVI) NC11) (Fig 7a, lane 4). Plasma ®bronectin
was cross-linked into high molecular weight complexes (at the top
of the gel) by FXIIIa (Fig 7b, lane 1).
DISCUSSION
We have demonstrated that a1(XVI)+ cell populations in the
super®cial dermis of normal skin contain FXIIIa+ and FXIIIa± cells.
The majority of a1(XVI)+ cells were found to be FXIIIa+, and a
few a1(XVI)+ cells were FXIIIa±. The population of a1(XVI)±/
FXIIIa+ was not detected. Similar results were obtained in the
lesional skin of dermato®broma in which tumor cells are considered
to be of FXIII+DD origin (Cerio et al, 1989b) and psoriatic skin in
which increased numbers of FXIIIa+ DD in the papillary dermis
have been reported (Cerio et al, 1989a). The results suggest that
a1(XVI)+ cell population in the super®cial dermal cells mostly
corresponds to FXIIIa+ cell population in both normal and diseased
conditions and a1(XVI) collagen can be a molecular marker of
FXIIIa+ DD. Clinically, it is often very important to differentiate
dermato®broma from its malignant counterparts, dermato®brosar-
coma and malignant ®brous histiocytoma. In the lesional skin of
dermato®brosarcoma and malignant ®brous histiocytoma, there
were no immunoreactive cells with anti-a1(XVI) collagen antibody
(unpublished observation).
The presence of a1(XVI)+FXIIIa±cells suggests that connective
tissue cells in the upper dermis contain very heterogeneous
populations. a1(XVI)+FXIIIa±cells in the super®cial dermis have
a similar phenotypic feature to that of skin ®broblast culture in
which ®broblasts express a1(XVI) collagen (Grassel et al, 1996,
1998; Akagi et al, 1999; Tajima et al, 2000) but do not express
FXIIIa as has been shown by reverse transcription±PCR and
western blot assays (see Figs 3b and 4b).
We have also demonstrated that expression of a1(XVI) collagen
and FXIIIa at mRNA and protein levels is coordinately enhanced
in the dendritic cells differentiated from peripheral blood mono-
cytes in vitro. This cell culture system using GM-CSF and IL-4 has
been designed to induce pheripheral blood monocytes into FXIIIa+
dendritic cells (Sallusto and Lanzavecchia, 1994), and has provided
evidence that DD are originated from monocytes. The induction of
a1(XVI) collagen as well as FXIIIa in this culture system will
support this hypothesis. It is of particular interest that a low level of
a1(XVI) collagen mRNA and a few number of a1(XVI)+ cells
were found in the adherent CD14+ peripheral blood monocytes
prior to treatment with GM-CSF/IL-4.
The colocalization of FXIIIa and a1(XVI) in the super®cial
connective tissue cells in vivo, and coordinate expression of FXIIIa
and a1(XVI) in the dendritic cells differentiated from CD14+
Figure 6. Factor XIIIa-catalyzed [3H]putrescine incorporation in
collagenous and noncollagenous proteins. [3H]putrescine (7 mCi)
and 750 nM of each proteins, N,N¢-dimethylcasein, ®bronectin, a1(XVI)
NC11, FXIII, type I collagen, type III collagen, a1(XVI) COL1´NC1
and BSA were incubated at 37°C for 0, 30, 60, and 120 min in the
presence of FXIIIa. Incorporation of [3H]putrescine was measured by
trichloroacetic acid precipitation. The net incorporation was calculated
by subtraction of the value in the presence of excess EDTA. Values
indicate mean 6 SEM.
Figure 7. Factor XIIIa-mediated cross-linking of NC11 domain
of (a) a1(XVI), (b) plasma ®bronectin, or (c) type III collagen. The
products of four different sets of incubation were analyzed by SDS±
PAGE followed by western blot. Each incubation was performed for
60 min at 37°C. Incubation 1 (lane 1) contains 50 mg protein substrates
per ml, 2.5 mg thrombin per ml, 20 mg per ml FXIII and 5 mM CaCl2.
Incubation 2 (lane 2) lacks thrombin. Incubation 3 (lane 3) contains
50 mM EDTA instead of CaCl2. Incubation 4 (lane 4) lacked
a1(XVI)NC11. The reaction mixture was heat-denatured in the presence
of 1% SDS and 1 mM DTT, and resolved on 5±20% SDS±PAGE. The
proteins were transblotted on to the membrane, then incubated with
anti-a1(XVI) NC11 anti-®bronectin or anti-type III collagen antibody.
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monocytes in vitro strongly suggest that there is an important
biologic relationship between the expression of type XVI collagen
and FXIIIa. FXIIIa is considered to catalyze the cross-linking of
®brin and stabilize clot formation at the ®nal stage of coagulation
pathway. Although the amino acid sequence of FXIIIa subunit
deduced from cDNA sequence does not contain a typical
hydrophobic leader sequence for secretion and suggests cytoplasmic
protein, the tetrameric plasma enzyme (a2b2) occurs by an
unknown secretion mechanism (Muszbek et al, 1996;
Aeschlimann and Thomazy, 2000). Indeed, we have shown the
presence of a considerable amount of FXIIIa in the conditioned
medium of the dendritic cells differentiated from monocytes. The
physiologic role of FXIII is not restricted to the area of hemostasis,
but possibly plays a part in connective tissue organization in wound
healing or repair. The previous reports that wound healing is
impaired in FXIII-de®cient patients (Lorand et al, 1980), FXIII
stimulates ®broblast proliferation and suppresses collagen biosynth-
esis by ®broblasts (Beck et al, 1961; Paye et al, 1989), FXIIIa
catalyzes the cross-linking of ®brin(ogen), ®bronectin itself, and
®bronectin to collagens type I, II, III, and V (Mosher et al, 1980;
Mosher, 1984) may support this idea. By contrast, it has been
demonstrated that FXIIIa, unlike tissue transglutaminase, does not
catalyze the cross-linking of aminopropeptide of type III collagen
(Bowness et al, 1987) or the cross-linking between collagens
(Mosher, 1984). Intermolecular cross-linking of a1(XVI) molecule
catalyzed by FXIIIa therefore may be unique in FXIIIa+ DD,
suggesting that the cross-linking may stabilize and support the
placement of DD in the extracellular tissue. Indeed, Sueki et al
(1993) have recently showed that DD are surrounded by a unique
matrix that may stabilize their placement in the dermis by an
electron microscopic observation.
a1(XVI) molecule consists of 11 noncollagenous and 10
collagenous domains. Except for a large N-terminal NC11 domain
of 312 residues, most of the NC domains of a1(XVI) molecule
were very short (11±39 residues). Because nontriple-helical globu-
lar domains in FACIT members have been reported to play an
essential part in their structural integrity and physiologic function,
such as NC1, NC2, and NC3 domains of type IX collagen (Wu et
al, 1992) and NC1 domain of type XVIII collagen (O'Reilly et al,
1997), we produced two recombinant proteins for transglutamina-
tion experiments corresponding to N-terminal noncollagenous
(NC11) and C-terminal collagenous and noncollagenous
(COL1´NC1) domains of a1(XVI) polypeptide rather than central
collagenous domains. We have demonstrated that the NC11
domain of the a1(XVI) chain is a potential site for FXIIIa-mediated
cross-linking. No de®nite consensus sequence for reactive
glutamine residues in the transglutaminase substrates has been
determined. The location of reactive glutamine residues in the
respective substrate proteins, however, appears to have several
common features. When two glutamine residues are directly
adjacent or when the glutamine residues are located within 15
amino acids from the NH2 or COOH terminus, they often
potentially function as amine acceptor sites (Aeschlimann et al,
1992). Although we did not determine the precise position of
reactive glutamine residue in NC11 domain in this study, on the
basis of these putative features of the sequences candidate glutamine
residues in the NC11 domain are found at amino acid positions 11
and 12 (PSQQEG) from the N-terminal end. The precise studies
using the smaller fusion proteins of the NC11 domain are now in
progress.
Type XVI collagen has been demonstrated to distribute widely
in the skin, heart, kidney, intestine, ovary, testis, eye, arterial wall,
and smooth muscle by in situ hybridization and immunohisto-
chemical study (Lai and Chu, 1996). FXIIIa+ dendritic cells also
ubiquitously occur in collagen-rich tissues, including skin, fascia,
tendon, arterial wall, and bone (Headington, 1986; Hoyo et al,
1993). Cross-linking of a1(XVI) collagen mediated by FXIIIa in
the DD appears to occur in other dendritic cell-rich tissues as well.
But we do not clarify whether FXIIIa is capable of cross-linking the
recombinant full-length a1(XVI) collagen chain. FACIT collagens
have been demonstrated to interact with the ®brils of major
collagens. For example, the association of type IX collagen with the
®bril of type II collagen is demonstrated by the presence of covalent
linkages between these two collagens (Wu et al, 1992). Type XII
and XIV collagens show a remarkable homology with type IX in
their C-terminal collagenous domain (COL1). This homology, and
consistent codistribution and copuri®cation of type I, type XII, and
XIV collagens suggest that these collagens may play a part on type I
collagen ®brils similar to the role of type IX on type II collagen
®brils (Keene et al, 1991; Nishiyama et al, 1994). Indeed, an
interaction of collagen XIV with type I collagen ®brils mediated by
decorin has been demonstrated (Fout et al, 1993). Although the
question whether type XVI collagen may interact with other
extracellular matrices such as interstitial (type I or III) collagens,
®bronectin, or decorin remains unanswered, FXIIIa-mediated
stabilization of type XVI collagen may play an essential part in
maintaining structural integrity of the FXIIIa+ dendritic cell-rich
tissues.
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